# Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

> **NCT04034927** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 61 (actual)

## Conditions studied

- Fallopian Tube Endometrioid Tumor
- Fallopian Tube High Grade Serous Adenocarcinoma
- Malignant Ovarian Endometrioid Tumor
- Ovarian High Grade Serous Adenocarcinoma
- Platinum-Sensitive Fallopian Tube Carcinoma
- Platinum-Sensitive Ovarian Carcinoma
- Platinum-Sensitive Primary Peritoneal Carcinoma
- Primary Peritoneal High Grade Serous Adenocarcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Fallopian Tube Endometrioid Adenocarcinoma
- Recurrent Ovarian Endometrioid Adenocarcinoma
- Recurrent Ovarian Serous Adenocarcinoma
- Recurrent Primary Peritoneal Carcinoma
- Recurrent Primary Peritoneal Endometrioid Adenocarcinoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Olaparib
- **BIOLOGICAL:** Tremelimumab

## Key facts

- **NCT ID:** NCT04034927
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-12-04
- **Primary completion:** 2021-07-31
- **Final completion:** 2027-02-21
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04034927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04034927, "Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04034927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*